Narcolepsy: Clinical features, co-morbidities & treatment

被引:0
|
作者
Peacock, Jeremy [1 ]
Benca, Ruth M. [1 ]
机构
[1] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA
关键词
Cataplexy; excessive daytime sleepiness; hypocretin; MSLT; narcolepsy; EXCESSIVE DAYTIME SLEEPINESS; ONSET REM PERIODS; QUALITY-OF-LIFE; GAMMA-HYDROXYBUTYRATE; HLA DQB1-ASTERISK-0602; CEREBROSPINAL-FLUID; PRACTICE PARAMETERS; AMERICAN-ACADEMY; CATAPLEXY; MODAFINIL;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Narcolepsy is a neurologic illness that typically begins in the second and third decades of life. It is chronic in nature and negatively impacts the quality of life of affected patients. The classic presentation is a tetrad of excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations. The exact cause remains unknown, but there is significant evidence that hypocretin deficiency plays an integral role. Some primary conditions that result in secondary narcolepsy include traumatic brain injury, congenital disorders, tumours, and strokes. Some medical and psychiatric disorders share characteristics of narcolepsy, at times leading to diagnostic inaccuracy. Other sleep disorders are commonly co-morbid. Diagnosis relies on patient history and objective data gathered from polysomnography and multiple sleep latency testing. Treatment focuses on symptom relief through medication, education, and behavioural modification. Both classic pharmacological treatments as well as newer options have significant problems, especially because of side effects and abuse potential. Novel modalities are being examined to expand options for treatment.
引用
收藏
页码:338 / 349
页数:12
相关论文
共 50 条
  • [41] Testosterone replacement treatment in older people with and without co-morbidities
    Zitzmann, Michael
    INTERNIST, 2020, 61 (06): : 549 - 557
  • [42] Interstitial cystitis - Cost, treatment and co-morbidities in an employed population
    Wu, EQ
    Birnbaum, H
    Mareva, M
    Parece, A
    Huang, ZH
    Mallett, D
    Taitel, H
    PHARMACOECONOMICS, 2006, 24 (01) : 55 - 65
  • [43] Treatment Of Obesity-Related Co-Morbidities With VBLOC Therapy
    Herrera, M. F.
    Toouli, J.
    Kulseng, B.
    Brancatisano, R.
    Zulewski, H.
    Pantoja, J. P.
    Kow, L.
    Johnsen, G.
    Brancatisano, A.
    Frey, D. M.
    Tweden, K. S.
    Billington, C. J.
    OBESITY SURGERY, 2011, 21 (08) : 998 - 998
  • [44] Psoriasis and co-morbidities - new aspects
    Shapiro, J.
    Pavlovski, L.
    Cohen, A.
    Hodak, E.
    David, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 39 - 39
  • [45] Co-morbidities in Heart Failure Preface
    Zannad, Faiez
    Ventura, Hector O.
    HEART FAILURE CLINICS, 2014, 10 (02) : XI - XI
  • [46] Sex differences in stroke co-morbidities
    Branyan, Taylor E.
    Sohrabji, Farida
    EXPERIMENTAL NEUROLOGY, 2020, 332
  • [47] Childhood obesity and its co-morbidities
    Misra, M
    Khan, N
    Khateeb, N
    Taub, A
    Anhalt, H
    Chin, D
    PEDIATRIC RESEARCH, 1999, 45 (04) : 94A - 94A
  • [48] CO-MORBIDITIES AND PROGNOSIS OF BACTEREMIA - REPLY
    PITTET, D
    SUTER, PM
    INTENSIVE CARE MEDICINE, 1994, 20 (05) : 400 - 400
  • [49] Respiratory co-morbidities in people with HIV
    Brown, James
    Smith, Colette
    Johnson, Margaret
    Lipman, Marc
    Abubakar, Ibrahim
    LANCET INFECTIOUS DISEASES, 2016, 16 (01): : 21 - 21
  • [50] Effects of co-morbidities on MS outcomes
    Marrie, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S47 - S48